KalVista Pharmaceuticals, Inc. Total Revenue

• KalVista Pharmaceuticals, Inc. showed a decrease of -21.3% in Total Revenue from 2019 to 2020.
• This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 7, 2022.
• XBRL data for this metric is available from 2016 to 2020 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2016: $975.0 thousand | Q4 2016: $197.0 thousand | Q1 2017: $248.0 thousand | Q2 2017: $114.0 thousand | Q3 2017: $96.0 thousand | Q3 2017: $96.0 thousand | Q4 2017: $1.13 million | Q4 2017: $1.13 million | Q1 2018: $2.33 million | Q1 2018: $2.33 million | Q2 2018: $4.84 million | Q2 2018: $4.84 million | Q3 2018: $3.72 million | Q4 2018: $5.59 million | Q1 2019: $3.89 million | Q2 2019: $2.93 million | Q3 2019: $3.37 million | Q4 2019: $3.92 million | Q1 2020: $1.58 million | Q2 2020: $3.82 million | Q3 2025: $1.43 million | Q3 2025: $13.69 million.
• Over the full 7 years of available data (2016 to 2020), KalVista Pharmaceuticals, Inc.'s Total Revenue has grown by 494.9%.
• Historical annual values: Fiscal year 2020: $12.69 million | Fiscal year 2019: $16.13 million | Fiscal year 2018: $8.39 million | Fiscal year 2018: $8.39 million | Fiscal year 2017: $1.50 million | Fiscal year 2017: $1.50 million | Fiscal year 2016: $2.13 million.
• Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: August 10, 2026